NCT03536767View on ClinicalTrials.gov

Open-Label Study of AG10 in Patients with Cardiomyopathy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Amyloid Cardiomyopathy
Interventions
DRUG

AG10

AG10 800mg twice daily, oral administration

Trial Locations (9)

10032

Columbia University, New York

29424

Medical University of South Carolina, Charleston

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

94143

University of California San Francisco, San Francisco

94304

Stanford University, Palo Alto

97239

Oregon Health & Science University, Portland

06520

Yale University, New Haven

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Eidos Therapeutics, a BridgeBio company

INDUSTRY

NCT03536767 - Open-Label Study of AG10 in Patients with Cardiomyopathy | Biotech Hunter | Biotech Hunter